A Phase 2 interventional study of Nifedipine (Adalat CR, BAYA1040) 80mg OD and Nifedipine (Adalat CR, BAYA1040) 40mg BID in Hypertension, sponsored by Bayer. Completed at 3 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-08.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing nifedipine in Hypertension — 3 open to participants now, 3 under way, 1 of them phase 3. Nifedipine · Hypertension.
Among the 29 studies testing nifedipine in Hypertension, this one is the 23rd largest by enrollment, is one of 3 that started in 2008, is one of 3 in phase 2, and was the 6th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →3 of the 29 studies testing nifedipine in Hypertension are open now, in 1 country. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+ · Women only
Loma Linda University · Sites in United States
Ages 18+ · Women only
Nebraska Methodist Health System · Sites in United States
Ages 19+ · Women only
By country, each count listing its studies:
Nifedipine: first FDA approval 1981 (PROCARDIA). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 9 · Phase 4 12
First in 2003; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 72 across the 29 interventional studies. Of the 20 that completed or were terminated, 4 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 29 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
33 studies in Hypertension by Bayer: none open now, none under way, none of them phase 3. Of 31 finished, 4 (13%) have results posted.
Among the 33 studies in Hypertension by Bayer, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2008, is one of 3 in phase 2, and was the 10th registered.
Bayer’s Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing nifedipine in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 33 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, 6 x 3 cross-over study. All patients who meet the entry criteria will be required to stop taking any other anti-hypertensive agents than Adalat CR (controlled release), if taken, before starting 4 weeks (±7days) open-label Adalat CR 40 mg once daily (OD) treatment phase (baseline treatment period). Of them, those who are confirmed with their eligibility as subjects for the present study at the end of the baseline treatment period will be randomly allocated to one of the 6 treatment sequences on the basis of a computer-generated randomization list. Subsequently, BAY A1040 CR tablet 40 mg OD, 40 mg twice daily (BID) or 80 mg OD will be administered to a total of 6 weeks, 2 weeks per each treatment period (Period 1-3) under double-blind conditions using BAY A1040 CR tablet 40 mg and its placebo as follows (Double-blind treatment period).
Issues on safety are addressed in the Adverse Event section.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Untreated or treated patients with antihypertensive agents whose blood pressure (BP) in sitting position at entry (Visit 1) is as follows.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
Drug: Nifedipine (Adalat CR, BAYA1040) 40mg OD
Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
Drug: Nifedipine (Adalat CR, BAYA1040) 40mg BID
Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
Drug: Nifedipine (Adalat CR, BAYA1040) 80mg OD
Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
Change of Sitting Blood Pressure
Changes of sitting SBP and DBP (trough values) from baseline (ie \[trough BP at the end of each period during the double-blind treatment period\] minus \[trough BP at the end of the baseline treatment period\])
Time frame: Baseline and after 2 weeks treatment
Differences of Systolic Blood Pressure Profile
Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)
Time frame: Baseline and after 2 weeks treatment
Differences of Diastolic Blood Pressure Profile
Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)
Time frame: Baseline and after 2 weeks treatment
Target Blood Pressure Achievement in Elderly (≥65)
Elderly subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP \<140 mm Hg and DBP \<90 mm Hg
Time frame: After 2 weeks treatment
Target Blood Pressure Achievement in Non-elderly (<65)
Non-elderly subjects (\<65 years) without diabetes mellitus or chronic renal disorder and target BP SBP \<130 mm Hg and DBP \<85 mm Hg
Time frame: After 2 weeks treatment
Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder
Subjects with diabetes mellitus or chronic renal disorders and target BP SBP \<130 mm Hg and DBP \<80 mm Hg
Time frame: After 2 weeks treatment
Target Blood Pressure Achievement in All Subjects
Subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP \<140 mm Hg and DBP \<90 mm Hg. Subjects (\<65 years) without diabetes mellitus or chronic renal disorder and target BP SBP \<130 mm Hg and DBP \<85 mm Hg. Subjects with diabetes mellitus or chronic renal disorders and target BP SBP \<130 mm Hg and DBP \<80 mm Hg.
Time frame: After 2 weeks treatment
47 subjects were recruited from 30 Jan 2008 to 11 May 2008 by 3 centers in Japan.
| Milestone | Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each | Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each | Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each |
|---|---|---|---|---|---|---|
| Started | 5 | 6 | 6 | 6 | 6 | 6 |
| Subjects received treatment | 5 | 6 | 6 | 6 | 6 | 6 |
| Completed | 5 | 5 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each | Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each | Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 6 | 6 | 6 | 6 |
| Completed | 5 | 5 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each | Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each | Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 6 | 6 | 6 | 6 |
| Completed | 5 | 5 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Changes of sitting SBP and DBP (trough values) from baseline (ie \[trough BP at the end of each period during the double-blind treatment period\] minus \[trough BP at the end of the baseline treatment period\])
| mm Hg | Nifedipine (Adalat CR, BAYA1040) 40 mg OD | Nifedipine (Adalat CR, BAYA1040) 40 mg BID | Nifedipine (Adalat CR, BAYA1040) 80 mg OD |
|---|---|---|---|
| Systolic Blood Pressure | -10.19 ± 1.24 | -19.88 ± 1.24 | -10.13 ± 1.24 |
| Diastolic Blood Pressure | -4.30 ± 0.65 | -8.28 ± 0.65 | -4.98 ± 0.65 |
Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)
| mm Hg | Nifedipine (Adalat CR, BAYA1040) 40 mg OD | Nifedipine (Adalat CR, BAYA1040) 40 mg BID | Nifedipine (Adalat CR, BAYA1040) 80 mg OD |
|---|---|---|---|
| At 0-hour post-dose | -11.35 ± 15.75 | -21.24 ± 11.56 | -9.91 ± 10.58 |
| At 2-hour post-dose | -4.91 ± 11.62 | -8.65 ± 11.19 | -11.97 ± 10.15 |
| At 4-hour post-dose | -6.18 ± 12.05 | -5.76 ± 11.25 | -7.85 ± 10.02 |
| At 6-hour post-dose | -6.56 ± 12.58 | -4.94 ± 9.31 | -7.26 ± 8.40 |
| At 8-hour post-dose | -7.88 ± 11.53 | -6.97 ± 10.23 | -7.88 ± 10.68 |
| At 10-hour post-dose | -4.79 ± 10.60 | -4.03 ± 10.64 | -6.56 ± 9.41 |
| At 12-hour post-dose | -5.59 ± 10.98 | -4.38 ± 9.31 | -6.00 ± 9.98 |
| At 24-hour post-dose | -8.97 ± 12.79 | -18.38 ± 8.34 | -10.21 ± 10.87 |
Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)
| mm Hg | Nifedipine (Adalat CR, BAYA1040) 40 mg OD | Nifedipine (Adalat CR, BAYA1040) 40 mg BID | Nifedipine (Adalat CR, BAYA1040) 80 mg OD |
|---|---|---|---|
| At 0-hour post-dose | -3.82 ± 6.40 | -8.12 ± 6.24 | -4.18 ± 5.54 |
| At 2-hour post-dose | -4.15 ± 7.27 | -5.47 ± 7.01 | -7.18 ± 5.89 |
| At 4-hour post dose | -3.44 ± 7.47 | -1.62 ± 8.11 | -3.68 ± 6.33 |
| At 6-hour post-dose | -5.56 ± 7.42 | -1.71 ± 7.20 | -3.85 ± 5.94 |
| At 8-hour post dose | -3.09 ± 6.13 | -3.18 ± 6.26 | -4.74 ± 6.30 |
| At 10-hour post-dose | -2.24 ± 6.34 | -1.74 ± 6.42 | -3.82 ± 7.26 |
| At 12-hour post-dose | -2.47 ± 6.59 | -2.15 ± 7.30 | -3.15 ± 6.97 |
| At 24-hour post dose | -5.00 ± 7.34 | -8.47 ± 5.39 | -5.82 ± 8.18 |
Elderly subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP \<140 mm Hg and DBP \<90 mm Hg
| participants | Nifedipine (Adalat CR, BAYA1040) 40 mg OD | Nifedipine (Adalat CR, BAYA1040) 40 mg BID | Nifedipine (Adalat CR, BAYA1040) 80 mg OD |
|---|---|---|---|
| Target Blood Pressure Achievement in Elderly (≥65) | 2 | 3 | 3 |
Non-elderly subjects (\<65 years) without diabetes mellitus or chronic renal disorder and target BP SBP \<130 mm Hg and DBP \<85 mm Hg
| participants | Nifedipine (Adalat CR, BAYA1040) 40 mg OD | Nifedipine (Adalat CR, BAYA1040) 40 mg BID | Nifedipine (Adalat CR, BAYA1040) 80 mg OD |
|---|---|---|---|
| Target Blood Pressure Achievement in Non-elderly (<65) | 3 | 10 | 4 |
Subjects with diabetes mellitus or chronic renal disorders and target BP SBP \<130 mm Hg and DBP \<80 mm Hg
| participants | Nifedipine (Adalat CR, BAYA1040) 40 mg OD | Nifedipine (Adalat CR, BAYA1040) 40 mg BID | Nifedipine (Adalat CR, BAYA1040) 80 mg OD |
|---|---|---|---|
| Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder | 0 | 4 | 1 |
Subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP \<140 mm Hg and DBP \<90 mm Hg. Subjects (\<65 years) without diabetes mellitus or chronic renal disorder and target BP SBP \<130 mm Hg and DBP \<85 mm Hg. Subjects with diabetes mellitus or chronic renal disorders and target BP SBP \<130 mm Hg and DBP \<80 mm Hg.
| participants | Nifedipine (Adalat CR, BAYA1040) 40 mg OD | Nifedipine (Adalat CR, BAYA1040) 40 mg BID | Nifedipine (Adalat CR, BAYA1040) 80 mg OD |
|---|---|---|---|
| Target Blood Pressure Achievement in All Subjects | 5 | 17 | 8 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nifedipine (Adalat CR, BAYA1040) 40 mg OD | — | 0/35 (0%) | 5/35 (14.3%) |
| Nifedipine (Adalat CR, BAYA1040) 40 mg BID | — | 0/34 (0%) | 7/34 (20.6%) |
| Nifedipine (Adalat CR, BAYA1040) 80 mg OD | — | 0/34 (0%) | 5/34 (14.7%) |
| Event | Nifedipine (Adalat CR, BAYA1040) 40 mg OD | Nifedipine (Adalat CR, BAYA1040) 40 mg BID | Nifedipine (Adalat CR, BAYA1040) 80 mg OD |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/35 | 0/34 | 2/34 |
| NasopharyngitisInfections and infestations | 0/35 | 2/34 | 0/34 |
| Stomach discomfortGastrointestinal disorders | 0/35 | 1/34 | 0/34 |
| Blood albumin decreasedInvestigations | 1/35 | 1/34 | 0/34 |
| Blood alkaline phosphatase increasedInvestigations | 0/35 | 1/34 | 0/34 |
| Blood creatine phosphokinase increasedInvestigations | 0/35 | 0/34 | 1/34 |
| Blood triglycerides increasedInvestigations | 0/35 | 1/34 | 0/34 |
| Haematocrit decreasedInvestigations | 0/35 | 1/34 | 1/34 |
| White blood cell count decreasedInvestigations | 0/35 | 0/34 | 1/34 |
| Lipid metabolism disorderMetabolism and nutrition disorders | 1/35 | 1/34 | 0/34 |
| Age, Continuous(years) | Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each | Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each | Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each | Total |
|---|---|---|---|---|---|---|---|
| Mean | 61.4 (55 to 68) | 63.6 (55 to 73) | 59.7 (55 to 65) | 64.3 (60 to 70) | 58.2 (37 to 67) | 59.7 (56 to 68) | 61.1 (37 to 73) |
| Sex: Female, Male(Participants) | Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each | Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each | Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 3 | 0 | 2 | 1 | 1 | 8 |
| Male | 4 | 2 | 6 | 4 | 5 | 5 | 26 |
| Blood Pressure (Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)) at Baseline(mm Hg) | Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each | Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each | Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each | Total |
|---|---|---|---|---|---|---|---|
| SBP at baseline | 150.00 ± 7.91 | 161.00 ± 16.67 | 156.33 ± 11.18 | 155.83 ± 10.96 | 156.33 ± 14.79 | 154.83 ± 13.53 | 155.89 ± 12.38 |
| DBP at baseline | 94.40 ± 4.98 | 95.00 ± 6.60 | 98.00 ± 6.45 | 91.00 ± 7.07 | 92.50 ± 3.45 | 89.83 ± 7.68 | 93.43 ± 6.40 |
| Heart rate (HR) at Baseline(beats / min) | Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each | Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each | Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each | Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each | Total |
|---|---|---|---|---|---|---|---|
| Mean | 64.20 ± 6.18 | 72.67 ± 13.95 | 79.00 ± 10.81 | 70.83 ± 5.42 | 68.50 ± 7.87 | 79.50 ± 17.84 | 72.69 ± 11.83 |
The record gives a start of Jan 2008, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nifedipine